LDL-cholesterol: A risk factor for coronary artery disease - From epidemiology to clinical trials

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. B, 1998, Pages

  Werner, Rachel M ^a   Pearson, Thomas A ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Cholesterol; Coronary artery disease; Low density lipoproteins

Indexed keywords

CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL; RESIN; SIMVASTATIN;

CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIET THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; KINESIOTHERAPY; LIPID BLOOD LEVEL; MORTALITY; PROGNOSIS; RELAXATION TRAINING; RISK FACTOR; VASCULAR DISEASE;

CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; RISK FACTORS; TRIGLYCERIDES;

EID: 0031860179     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Steinberg D. Antioxidants and atherogenesis: A current assessment. Circulation 1991;84:1420-5.
2. Cathcart MK, Morel DW, Chisolm GM. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 1985;38:341-50.
3. Fogelman AM, Schechter I, Seager J, et al. Malondialdehyde alteration of low density lipoprotein leads to ckolesteryl-ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980;77:2214-8.
4. Flavahan NA Atherosclerosis or lipid-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992;85:1927-38.
5. Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med 1986;314:488-500.
6. Fuster V, Badimon L, Badimon J, et al. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992;326:242-50.
7. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82:I138-46.
8. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;ii:533-7.
9. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
10. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from CVD in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
11. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary disease in population with low cholesterol concentrations. Br Med J 1991;303:276-82.
12. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
13. Carlson LA, Rosenhamer G Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
14. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA 1972;220:996-1008.
15. Roussow JE. Secondary prevention of coronary heart disease. In: Rifkind BM, ed. Lowering Cholesterol in High-Risk Individuals and Populations. New York: Marcel Dekker, 1995:49-67.
16. Lipid Research Clinics Program. The Lipid Research Clinic Coronary Drug Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
17. Frick MH, Elo O, Heinonen O, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
18. Gordon KL. Cholesterol lowering and total mortality. In: Rifkind BM, ed. Lowering Cholesterol in High-Risk Individuals and Populations. New York: Marcel Dekker, 1995:33-48.
19. Brown GB, Zhao Y-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-9.
20. Furberg CD, Byington RP, Crouse JR, et al. Pravastatin, lipids, and major coronary events. Am J Cardiol 1994;73:1133-4.
21. Furberg CD, Adams HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.
22. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993;72:1031-7.
23. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
24. Sacks FM, Pfeiler MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
25. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997;336:153-62.
26. Tonkin AM for the Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID). Presented at the American Heart Association 70th Scientific Sessions, Orlando, November 9 to 12, 1997.
27. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
28. Downs JR, Beere PA, Whitney E, et al. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997;80:287-93.
29. Gotto AM Jr for AFCAPS-TexCAPS. Presented at the American Heart Association 70th Scientific Sessions, Orlando, November 9 to 12, 1997.
30. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-8.
31. Herbert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997;278:313-21.
32. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol: A metaanalysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50.
33. Crouse JR IIIrd, Byington RB, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-10.
34. Wittels EH, Hay JW, Gotto AM. Medical costs of coronary artery disease in the United States. Am J Cardiol 1990;65:432-40.
35. Cohen DJ, Goldman L, Weinstein MC. The cost-effectiveness of programs to lower serum cholesterol. In: Rifkind BM, ed. Lowering Cholesterol in High-Risk Individuals and Populations. New York: Marcel Dekker, 1995:311-36.
36. Goldman L, Garber AM, Grover SA, Hlatky MA. Cost-effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-30.
37. Kinosian BP, Eisenberg JM. Cutting into cholesterol: Cost-effective alternatives for treating hypercholesterolemia. JAMA 1988;259:2249-54.
38. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: Cost-effectiveness of pharmacologic management. JAMA 1990;264:3025-33.
39. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.
40. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-24.
41. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
42. Buchwald H, Varco RL, Matts JP, et al. Effect of partial deal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias. N Engl J Med 1990;323:946-55.
43. Omish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-33.
44. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
45. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-8.
46. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12.
47. Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study. Lancet 1992;339:563-9.
48. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-90.
49. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group Ann Intern Med 1993;119:969-76.
50. Furberg CD, Pitt B, Byington AP, et al Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995;76:60C-63C.
51. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994,89:959-68.
52. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study. Lancet 1994;344:633-8.
53. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-40.
54. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-86.